Hendrik W Reesink
Affiliation: Academic Medical Center
Country: The Netherlands
- Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized studyHendrik W Reesink
Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Gastroenterology 131:997-1002. 2006..4A protease of hepatitis C and has antiviral activity in vitro. This phase I, placebo-controlled, double-blind study evaluated the antiviral activity, pharmacokinetics, and safety of VX-950 in patients with chronic hepatitis C (CHC)...
- Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patientsHenk W Reesink
epartment of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Gastroenterology 138:913-21. 2010..In a first-in-human trial, we tested the safety, tolerability, and pharmacokinetics of the macrocyclic HCV NS3/4A protease inhibitor TMC435 in healthy volunteers, followed by HCV genotype 1-infected patients to assess antiviral activity...
- Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevirXiomara V Thomas
Academic Medical Center, Department of Medical Microbiology, Section of Clinical Virology, Amsterdam, The Netherlands
PLoS ONE 7:e41191. 2012..The aim of this study was to assess using ultra-deep pyrosequencing, whether after 4 years follow-up, the frequency of resistant variants is increased compared to pre-treatment frequencies following 14 days of telaprevir treatment...
- Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study designDaphne M Hotho
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
Antivir Ther 17:365-75. 2012..Two clinical trials investigated the safety, tolerability, pharmacokinetics and antiviral activity of PHX1766 in healthy volunteers (HV) and chronic hepatitis C patients, by use of a dose-adaptive overlapping clinical trial design...
- Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7Andre Boonstra
Department of Gastroenterology and Hepatology, Erasmus Medical Center University Hospital, Rotterdam, The Netherlands
Antivir Ther 17:657-67. 2012..ANA773, an oral prodrug of a small-molecule Toll-like receptor (TLR)7 agonist, induces a dose-related decrease in serum HCV RNA levels in chronic hepatitis C patients...
- Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profilesJoep de Bruijne
Department of Gastroenterology and Hepatology, AMC Liver Center, University of Amsterdam, Amsterdam 1100 DD, The Netherlands
J Clin Microbiol 47:3832-8. 2009..HCV-4-specific agents are drastically needed to improve treatment response rates and decrease the future burden of HCV-4-related disease...
- Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patientsR Bart Takkenberg
Department of Gastroenterology and Hepatology, AMC Liver Center, Center for Infectious Disease and Immunology CINIMA, University of Amsterdam and Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
Eur J Gastroenterol Hepatol 22:952-60. 2010..Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) may become an important predictor for treatment outcome or long-term follow-up...
- Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsTara L Kieffer
Vertex Pharmaceuticals Inc, Cambridge, MA 02139, USA
Hepatology 46:631-9. 2007....
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CNicole Forestier
Saarland University Hospital, Homburg, Germany
Hepatology 46:640-8. 2007....